KUALA LUMPUR, May 2026 – Prodia The CRO recently concluded a high-impact participation at CRM Trial Connect 2026, held from May 7–8 at the Connexion Conference & Event Centre (Nexus), Bangsar South. This 5th edition of Clinical Research Malaysia’s flagship event, themed “Asia’s Rise in Clinical Trials,” served as a pivotal platform for Prodia The CRO to strengthen its regional footprint and explore the evolving landscape of global clinical development.
Driving Collaborative Innovation
The conference gathered over 1,100 global delegates, including regulators, sponsors, and leading Clinical Research Organizations (CROs). For Prodia The CRO, the event was a strategic opportunity to engage with international stakeholders and align with the latest regional advancements.
Key themes from the symposiums included:
- The Rise of Asia: Strategic discussions on why Southeast Asia is becoming the preferred destination for oncology and biotech research.
- Regional Integration: Exploring the synergy between ASEAN member states to create a unified and competitive clinical research ecosystem.
Navigating the Regulatory Frontier:
A core highlight of the event was the deep dive into Southeast Asia’s regulatory landscape. Prodia The CRO actively participated in sessions featuring prominent Indonesian voices, focusing on streamlining multicenter trial approvals and harmonizing standards.
Key regulatory discussions included:
- BPOM Insights: Representatives from the Indonesian Food and Drug Authority (BPOM) outlined recent updates in clinical trial submission processes, emphasizing digital transformation and accelerated pathways for high-need therapeutic areas.
- INACRC Perspectives: The Indonesia Clinical Research Center (INACRC) highlighted the importance of centralized coordination to enhance the visibility and readiness of Indonesian research sites for global sponsors.
- Expert Analysis by Prof. Jarir: Prof. Jarir At Thobari provided a critical academic and practical perspective on bridging the gap between international ICH GCP E6 R3 standards and local implementation. His insights on health economics and clinical outcomes provided a robust framework for improving trial efficiency in Indonesia.
Strengthening the Indonesia-Malaysia Research Corridor
As a premier Indonesian CRO, Prodia’s presence underscored the importance of cross-border collaboration. The team engaged in high-level networking and the ASEAN Leaders Forum, reinforcing the partnership between Indonesia and Malaysia in making the region a global powerhouse for clinical trials.
“Our participation at CRM Trial Connect 2026 reinforces Prodia The CRO’s commitment to operational excellence. The collaboration between BPOM, INACRC, and experts like Prof. Jarir ensures that the Indonesian research landscape remains transparent, compliant, and attractive to global investment.”
Looking Ahead
The insights gained from CRM Trial Connect 2026 will further enhance Prodia The CRO’s service delivery, particularly in optimizing site startup phases and ensuring robust quality assurance. Prodia The CRO remains dedicated to bridging the gap between innovative research and real-world clinical application, ensuring Indonesia’s vital role in the global healthcare ecosystem.
For more information on our clinical trial services and regional capabilities, visit prodiathecro.com.
